Here are the latest updates from the pharmaceutical industry, explained in simple terms:
1. **Charles River Laboratories**: This company is focusing more on its main business by separating its contract manufacturing division. This move aims to boost growth and efficiency.
2. **Lipid Nanoparticle Discovery**: Scientists have found a way to improve drug delivery using lipid nanoparticles, which could speed up the development of new RNA-based medicines.
3. **Novartis’ Investment in Texas**: Novartis is building a new facility in Texas to make cancer treatments. This is part of their $23 billion plan to improve their US operations.
4. **Novo Nordisk and Vivtex**: Novo Nordisk is teaming up with Vivtex to develop new oral therapies for obesity and diabetes. They are investing $2.1 billion in this partnership.
5. **GSK’s Acquisition**: GSK has bought a company called 35Pharma for nearly $1 billion to boost its work on respiratory, immunology, and inflammatory diseases.
6. **AbbVie’s Investment in Illinois**: AbbVie is investing $380 million to expand its manufacturing in Illinois. This is part of their $100 billion plan to improve research and development in the US.
7. **FDA’s New Guidance**: The FDA is creating new rules to help approve treatments for very rare diseases. This is the first framework of its kind.
8. **Gilead’s Acquisition**: Gilead has bought Arcellx for $8 billion to add to its cell therapy portfolio, building on their previous collaboration.
9. **EU Court Ruling**: The EU court has dismissed a request from pharmaceutical companies to cancel certain wastewater rules. The industry association EFPIA says important questions remain.
10. **Sustainable Manufacturing**: Scientists are exploring the use of microbial-derived hydrogen from leftover bread to make pharmaceuticals in a more sustainable way.
11. **Lilly’s Crohn’s Drug**: Lilly’s drug Omvoh has shown long-term benefits for Crohn’s disease patients, helping them stay steroid-free for three years.
12. **Daiichi Sankyo’s New R&D Head**: Dr. John Tsai, formerly from Novartis, will now lead Daiichi Sankyo’s global research and development operations.
13. **FDA’s New Policy**: The FDA has set new requirements for drug approvals, which now include a single, robust study plus confirmatory evidence instead of two trials.
14. **Johnson & Johnson’s Investment**: Johnson & Johnson is investing $1 billion in a new cell therapy manufacturing plant in Pennsylvania, part of their $55 billion plan to expand US manufacturing.
15. **Recipharm’s Collaboration**: Recipharm has sold a manufacturing site to Scinai as part of a long-term partnership to develop and supply biologics.